C
Carlos L. Morais
Researcher at Johns Hopkins University
Publications - 13
Citations - 660
Carlos L. Morais is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: PTEN & Prostate cancer. The author has an hindex of 11, co-authored 13 publications receiving 568 citations. Previous affiliations of Carlos L. Morais include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer
Thomas U. Ahearn,Andreas Pettersson,Andreas Pettersson,Ericka M. Ebot,Travis Gerke,Rebecca E. Graff,Rebecca E. Graff,Carlos L. Morais,Jessica Hicks,Kathryn M. Wilson,Jennifer R. Rider,Howard D. Sesso,Michelangelo Fiorentino,Richard Flavin,Stephen P. Finn,Edward Giovannucci,Massimo Loda,Meir J. Stampfer,Angelo M. De Marzo,Lorelei A. Mucci,Tamara L. Lotan +20 more
TL;DR: PTEN loss is independently associated with increased risk of lethal progression, particularly in the ERG fusion-negative subgroup, and these validated and inexpensive IHC assays may be useful for risk stratification in prostate cancer.
Journal ArticleDOI
Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.
Carlos L. Morais,Jeong S. Han,Jennifer Gordetsky,Michael S. Nagar,Ann E. Anderson,Stephen J. Lee,Jessica Hicks,Ming Zhou,Cristina Magi-Galluzzi,Rajal B. Shah,Jonathan I. Epstein,Angelo M. De Marzo,Tamara L. Lotan +12 more
TL;DR: It is demonstrated that PTEN and ERG immunostaining may be helpful to resolve this differential diagnosis of intraductal carcinoma of the prostate and high-grade prostatic intraepithelial neoplasia in radical prostatectomies, and suggested that these markers are diagnostically useful in the needle biopsy setting.
Journal ArticleDOI
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH.
Tamara L. Lotan,Wei Wei,Olga Ludkovski,Carlos L. Morais,Liana B. Guedes,Tamara Jamaspishvili,Karen Lopez,Sarah T. Hawley,Ziding Feng,Ladan Fazli,Antonio Hurtado-Coll,Jesse K. McKenney,Jeff Simko,Peter R. Carroll,Martin E. Gleave,Daniel W. Lin,Peter S. Nelson,Peter S. Nelson,Ian M. Thompson,Lawrence D. True,James D. Brooks,Raymond S. Lance,Dean A. Troyer,Jeremy A. Squire,Jeremy A. Squire +24 more
TL;DR: A clinical-grade, automated, and inexpensive immunohistochemical assay to detect PTEN loss is developed and is a sensitive method for detection of homozygous PTEN gene deletions.
Journal ArticleDOI
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy
Jeffrey J. Tosoian,Fawaz Almutairi,Carlos L. Morais,Stephanie Glavaris,Jessica Hicks,Debasish Sundi,Debasish Sundi,Elizabeth B. Humphreys,Misop Han,Angelo M. De Marzo,Ashley E. Ross,Scott A. Tomlins,Edward M. Schaeffer,Edward M. Schaeffer,Bruce J. Trock,Tamara L. Lotan +15 more
TL;DR: PTEN and ERG alterations in prostate cancer are less likely in African-American than in European-American men, however, PTEN loss remains associated with poor prostate cancer outcomes among African- American men.
Journal ArticleDOI
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer
Tamara L. Lotan,Wei Wei,Carlos L. Morais,Sarah T. Hawley,Ladan Fazli,Antonio Hurtado-Coll,Dean A. Troyer,Jesse K. McKenney,Jeff Simko,Peter R. Carroll,Martin E. Gleave,Raymond S. Lance,Daniel W. Lin,Peter S. Nelson,Ian M. Thompson,Lawrence D. True,Ziding Feng,James D. Brooks +17 more
TL;DR: It is found that loss of the PTEN tumor suppressor gene in prostate tumors as assessed by tissue staining is correlated with shorter time to prostate cancer recurrence after radical prostatectomy and that there is no statistically significant interaction between PTEN and ERG status for RFS.